Article

Discovering DNA: Friedrich Miescher and the early years of nucleic acid research

Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Vienna, Austria,
Human Genetics (Impact Factor: 4.52). 02/2008; 122(6):565-81. DOI: 10.1007/s00439-007-0433-0
Source: PubMed

ABSTRACT In the winter of 1868/9 the young Swiss doctor Friedrich Miescher, working in the laboratory of Felix Hoppe-Seyler at the University of Tübingen, performed experiments on the chemical composition of leukocytes that lead to the discovery of DNA. In his experiments, Miescher noticed a precipitate of an unknown substance, which he characterised further. Its properties during the isolation procedure and its resistance to protease digestion indicated that the novel substance was not a protein or lipid. Analyses of its elementary composition revealed that, unlike proteins, it contained large amounts of phosphorous and, as Miescher confirmed later, lacked sulphur. Miescher recognised that he had discovered a novel molecule. Since he had isolated it from the cells' nuclei he named it nuclein, a name preserved in today's designation deoxyribonucleic acid. In subsequent work Miescher showed that nuclein was a characteristic component of all nuclei and hypothesised that it would prove to be inextricably linked to the function of this organelle. He suggested that its abundance in tissues might be related to their physiological status with increases in "nuclear substances" preceding cell division. Miescher even speculated that it might have a role in the transmission of hereditary traits, but subsequently rejected the idea. This article reviews the events and circumstances leading to Miescher's discovery of DNA and places them within their historic context. It also tries to elucidate why it was Miescher who discovered DNA and why his name is not universally associated with this molecule today.

1 Follower
 · 
978 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this review several types of interactions between metal ions and DNA are given, starting from basic binding to the use of metal complexes in cancer treatment and diagnostics. Metal cations help to neutralize the negative charge of DNA and thus enable the normal functions of DNA but many other interactions are also possible and are discussed in this paper. Various consequences of such interactions can be reversible (e. g. conformational changes) or irreversible (e. g. cleavage). It is known that some metal ions can also damage DNA which can provoke mutations and in some cases leads to cancer. It is clear that we know a lot about metal-DNA interactions but much more information is needed to understand the role of metal ions completely and to use this knowledge successfully.
    Current topics in medicinal chemistry 11/2011; 11(21):2661-87. DOI:10.2174/156802611798040787 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tesis Univ. Granada. Departamento de Fisiología. Leída el 21 de mayo de 2010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since nucleic acids (DNA and RNA) play very important roles in cells, they are molecular targets of many clinically used drugs, such as anticancer drugs and antibiotics. Because of clinical demands for treating various deadly cancers and drug-resistant strains of pathogens, there are urgent needs to develop novel therapeutic agents. Targeting nucleic acids hasn’t been the mainstream of drug discovery in the past, and the lack of 3D structural information for designing and developing drug specificity is one of the main reasons. Fortunately, many important structures of nucleic acids and their protein complexes have been determined over the past decade, which provide novel platforms for future drug design and discovery. In this review, we describe some useful nucleic acid structures, particularly their interactions with the ligands and therapeutic candidates or even drugs. We summarize important information for designing novel potent drugs and for targeting nucleic acids and protein-nucleic acid complexes to treat cancers and overcome the drug-resistant problems. Kewyordsnucleic acid targets–DNA and RNA–protein-nucleic acid complexes–DNA duplex and junction–G-quadruplex–ribozyme–riboswitch–ribosome–topoisomerase–inhibitors–antibiotics–structure-based drug design–therapeutic agents
    Science China-Chemistry 01/2011; 54(1):3-23. DOI:10.1007/s11426-010-4174-x · 1.52 Impact Factor